This finding may be indicative of the resource-optimisation allocation hypothesis
As background, the Food and Drug Act in sec 503A provides that bulk drug substances that either 1) lack a USP or NF monograph, or 2) are not components of FDA-approved drug products, cannot be used in compounding unless they appear on a list created under Section 503A
They found that those who took GLP-1s had a 46% lower risk of death from any cause during the follow-up period of about 5.5 years
Giugliano D, Longo M, Maiorino MI, Bellastella G, Chiodini P, Solerte SB, Esposito K
Other factors such as insurance coverage, cost, availability, and patient preference for administration likely impacted which GLP-1RAs were used
S.LiaudetL